rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GMAB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
      Nov 11Yahoo FinanceGMAB
      Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
      Nov 10Yahoo FinanceGMAB
      Capital Increase in Genmab as a Result of Employee Warrant Exercise

      Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,961 shares at DKK 1,362.5,17,676 shares at DKK 1,615,949 shares at DKK 1,948,25,635 shares at DKK 2,070,6,1

      Nov 10Yahoo FinanceGMAB
      Genmab shares rise 4% on J&J cancer drug FDA approval
      Nov 9Investing.comGMAB
      Is Genmab (CPSE:GMAB) Fully Priced After Holding 2026 Guidance Steady?
      Nov 8Yahoo FinanceGMAB
      Genmab (GMAB) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 6The Globe and MailGMAB
      Moody’s lifts Genmab outlook to positive on pipeline progress, debt reduction
      Nov 6Investing.comGMABMCO
      Genmab shares fall 3% after Q3 revenue slightly misses expectations
      Nov 6Investing.comGMAB
      Why is Genmab stock sliding today?
      Nov 6Investing.comGMAB
      Genmab AS (GMAB) (Q3 2026) Earnings Call Highlights: Revenue Jumps 22% as Epkinly and Pipeline ...
      Nov 6Yahoo FinanceGMAB
      Genmab AS ADR earnings beat by $0.20, revenue fell short of estimates
      Nov 6Investing.comGMAB
      What Genmab A/S (GMAB) Said on Its Q3 Earnings Call
      Nov 5Yahoo FinanceGMAB
      Genmab Q3 2026 Earnings Call Transcript
      Nov 5BenzingaGMAB
      Genmab nine-month revenue rises 22% as late-stage pipeline delivers

      Investing.com -- Genmab reported a 22% rise in revenue for the first nine months of 2026 on Thursday, driven by higher royalties from Darzalex and Kesimpta and stronger sales of its cancer drug Epkinly. The Danish biotech maintained its full-year guidance.

      Nov 5Yahoo FinanceGMAB
      Genmab shares fall 3% after Q3 revenue slightly misses expectations
      Nov 5Yahoo FinanceGMAB
      Genmab Announces Financial Results for the Nine Months of 2026
      Nov 5Yahoo FinanceGMAB
      Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting

      Media Release COPENHAGEN, Denmark; November 4, 2026 Twenty-two abstracts underscore the versatility of epcoritamab as monotherapy and in combination across multiple disease subtypes and in earlier lines of therapy Six oral presentations include first data disclosure from the Phase 3 EPCORE® DLBCL-4 study evaluating epcoritamab in combination with lenalidomide in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Genmab A/S (Nasdaq: GMAB) announced today that 22 abst

      Nov 4Yahoo FinanceGMAB
      Genmab Stock Price Shock Puts 3 Oncology Biotech Names In Focus
      Nov 3Yahoo FinanceGMAB
      A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

      Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.

      Nov 3CNBCGMAB
      H.C. Wainwright raises Genmab stock price target to $70 on trial data
      Oct 30Investing.comGMAB
      Genmab’s Stellar Cancer-Drug Data Fuels Stock’s $10 Billion Week
      Oct 30BloombergGMAB
      Can Genmab (CPSE:GMAB) Still Be Undervalued After Its Trial Wins?
      Oct 29Yahoo FinanceGMAB
      Analysts’ Top Healthcare Picks: Citius Oncology (CTOR), Genmab (GMAB)

      Tipranks Press Release.

      Oct 29The Globe and MailGMAB
      Genmab: Why I'd Wait Before Buying After Stunning Series Of Study Results

      Genmab stock surged on strong Phase 3 cancer data, but valuation and patent risks remain. Click here to read this recent analysis of GMAB stock.

      Oct 29Seeking AlphaGMAB
      Genmab Shares Soar on Success in Head and Neck Cancer

      U.S.-traded shares of Genmab jumped 28% Wednesday after the Danish drugmaker said its experimental drug, petosemtamab, cut the risk of death by half in a late-stage study of patients with head and neck cancer. Patients got the drug alongside Merck's blockbuster immunotherapy Keytruda, and were compa

      Oct 28WSJGMAB
      Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
      Oct 28Yahoo FinanceGMAB
      Genmab Stock Hits 52-Week High - Here's Why
      Oct 28BenzingaGMAB
      GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know
      Oct 28Yahoo FinanceGMAB
      Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%

      Genmab scores a ‘hat trick’ with positive data for its experimental cancer drug, petosemtamab, Jefferies says.

      Oct 28Barron'sGMAB
      Genmab Shares Hit Record as Cancer Trial Extends Drugmaker’s Run
      Oct 28BloombergGMAB
      Genmab’s petosemtamab trial cuts death risk by 50% in cancer
      Oct 28Investing.comGMAB
      Genmab stock rises on Phase 3 cancer trial data (GMAB:NASDAQ)

      Genmab (GMAB) stock surges as head and neck cancer cuts death risk by 50%, with Merck’s (MRK) Keytruda sending Bicara Therapeutics (BCAX) lower. Read more here.

      Oct 28Seeking AlphaGMABMRK
      Why is Genmab stock surging today?
      Oct 28Investing.comGMAB
      Genmab stock surges 16% on positive cancer trial results
      Oct 28Investing.comGMAB
      Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
      Oct 28Yahoo FinanceGMAB
      J.P. Morgan upgrades Genmab on cancer drug growth potential
      Oct 27Investing.comGMAB
      Genmab: Positive Data for Rina-S and Petosemtamab Strengthen Multifranchise Oncology Strategy
      Oct 27MorningstarGMAB
      JPMorgan upgrades Genmab stock rating on drug trial outlook
      Oct 27Investing.comGMAB
      Petosemtamab Trial Results May Change The Case For Genmab Stock
      Oct 26Yahoo FinanceGMAB
      Genmab's Encouraging Oncology Data Boosts Investor Optimism
      Oct 26BenzingaGMAB
      Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
      Oct 26Yahoo FinanceGMABINCY
      Genmab Shares Jump After Positive Cancer Study Results
      Oct 26WSJGMAB
      Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

      Media Release COPENHAGEN, Denmark; October 26, 2026 Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (r/m HNSCC), with responses observed across HPV-positive and HPV-negative diseasePhase 3 program in 1L HNSCC is ongoing, with topline data anticipated later this year Genmab A/S (Nasdaq: GMAB) today announced updated results from a Phase 2

      Oct 26Yahoo FinanceGMAB
      Genmab Soars as Cancer Drug Impresses in a Late-Stage Trial
      Oct 26BloombergGMAB
      Why is Genmab stock surging today?
      Oct 26Investing.comGMAB
      Genmab shares jump 13% on colorectal cancer drug trial results
      Oct 26Investing.comGMAB
      Genmab, Incyte team up to develop experimental colorectal cancer treatment (INCY:NASDAQ)

      Genmab and Incyte team up on a Phase 1/2 colorectal cancer trial targeting KRAS G12D.

      Oct 25Seeking AlphaGMABINCY
      Genmab reports phase 2 trial data for colorectal cancer drug
      Oct 25Investing.comGMAB
      Does Genmab Trial Deal Change The Bull Case For Incyte (INCY)?
      Oct 24Yahoo FinanceGMABINCY
      Corcept Therapeutics plunges 20% on Genmab cancer data (CORT:NASDAQ)
      Oct 23Seeking AlphaCORTGMAB

      This is the newest page. Registered accounts read further back.